Lab Hotel at Stevenage Bioscience Catalyst now fully booked

Pictured L-R: Dr Sally Ann Forsyth OBE, CEO at SBC; Godwin Long In Lo, Research Scientist, Dr Ming-Tsung Wu, COO, Leo Chi U Seak, CEO at Genenet Technology; Hind Abdalaal, Scientist, Annelise Soulier, CSO and Pedro Correa De Sampaio, CEO at Neobe Therapeutics; James Latham, Leasing and Development Director at SBC

  • Two new companies, Neobe Therapeutics and Genenet Technology, have been awarded space in the Lab Hotel
  • The Lab Hotel provides free laboratory and office accommodation for start-up companies for six months
  • Companies in the Lab Hotel have access to scientific and business support while they develop their innovations and secure their next round of funding.

Stevenage Bioscience Catalyst (SBC) has awarded space in its Lab Hotel to start-ups Neobe Therapeutics and Genenet Technology. The Lab Hotel is a unique facility offering free lab and office accommodation for six months. The facility is now at capacity with four start-ups receiving scientific and business support, access to SBC’s networks and introductions to investors to help their business grow and develop. 

Pedro Correa de Sampaio, CEO of Neobe Therapeutics, said, “We are extremely excited to move into the Lab Hotel and join the SBC community. As an early-stage therapeutics company with a limited budget, the access to state of the art laboratory equipment provided by the Lab Hotel will make a significant difference in our research programme, enabling us to reach our research milestones faster and more effectively. We also look forward to interacting with our fellow residents and learning from other founders in the advanced therapies space.”

Leo Chi U Seak CEO of Genenet Technology, said, “It’s our great pleasure to be selected to join the Lab Hotel. We are very impressed by the facilities and working environment here. As an early-stage start-up company, we struggled to find a suitable lab space. The Lab Hotel provides all we need to start our project quickly and gives us opportunities for collaboration. GeneNet Technology is looking forward to scaling up our business at SBC and developing better solutions for drug discovery and bioproduction.

As part of its commitment to supporting early-stage start-ups, SBC opened the Lab Hotel in 2020. Its purpose is to help start-ups working in advanced therapeutics and drug discovery to develop their innovations and secure their next round of funding. 

Dr Sally Ann Forsyth OBE, CEO at SBC, said, “We are delighted that Genenet Technology and Neobe Therapeutics have joined the Lab Hotel and the SBC community. Providing support for the translation and commercialisation of early-stage research is part of SBC’s vision. The Lab Hotel has already given nine young life sciences companies access to the facilities and help they need to take their innovative ideas to the next stage.”

SBC is a leading location for the development and commercialisation of cutting-edge therapeutics. Around 45 life sciences companies are based at SBC, creating an exciting, knowledgeable and collegiate community where interaction and collaboration are the norm.

To find out more about the Lab Hotel or make an application, see SBC’s website or email

About Stevenage Bioscience Catalyst

Stevenage Bioscience Catalyst is a world-leading science park of global significance and located at the centre of the largest cluster of cell and gene therapy companies in Europe. It provides a supportive environment to help companies grow by providing access to specialist equipment, mentoring and finance suited to their stage of development.  Since its opening in 2012, occupier companies have secured £2.9bn in finance making the cluster one of the most attractive for investment in biotechnology in the UK.

About Neobe Therapeutics

Neobe is developing a platform for the engineering of programmable live biotherapeutics, which can colonize solid tumours and remodel their local microenvironment. By removing barriers to immune infiltration in a safe and localized way, Neobe’s recombinant live biotherapeutics can potentially double the number of cancer patients that respond to existing immunotherapeutic strategies. Visit

About Genenet Technology

Genenet Technology (UK) Ltd integrates state-of-art deep learning neural networks into the gene circuit design. This unleashes the potential of genetic design into previously impossible applications. Currently, they are collaborating with partners to tackle problems in cardiac drug development and bioproduction.